T-cell prolymphocytic leukemia · 2 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Alemtuzumab monotherapy Variant #03 | — | R 267 680 | 7d | ~15.0 mo | — | ~1 | ~R 267 680 PFS proxy · indirect | — |
Pentostatin and Alemtuzumab Variant #01 Partial | — | R 146 007 | 7d | — | — | ~12 | ~R 949 046 indirect | — |
2 of 2 regimens shown